Scope of the Study
The coronavirus (COVID-19) disease is affecting 210 countries and territories around the world and 2 international conveyances. The major players are investing in the research and development activities of the coronavirus vaccine. In the race to develop a vaccine to end the COVID-19 pandemic, governments, charities and Big Pharma firms are sinking billions of dollars into bets with extraordinarily low odds of success. They are ensuring quick development of new coronavirus vaccine as well as it is ready to distribute as soon as it's approved. In the United States, the Biomedical Advanced Research and Development Authority (BARDA), a federal agency that funds disease-fighting technology, has recently announced that it invests billions to support coronavirus vaccine development and the scale-up of manufacturing for promising candidates.
The market study is being classified by Type (Government and Private Firms), by Application (Hospitals, Research Laboratories, Clinics and Others) and major geographies with country level break-up.
Serum Institute of India (India), BioNTech SE (Germany), Pfizer Inc. (United States), Gilead Sciences Inc. (United States), GlaxoSmithKline (United States), Roche Holding AG (Switzerland), Inovio Pharmaceuticals, Inc. (United States), Moderna Inc. (United States), Novavax Inc. (United States) and AbbVie Inc. (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Coronavirus Vaccine Investment market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Coronavirus Vaccine Investment market by Type, Application and Region.
On the basis of geography, the market of Coronavirus Vaccine Investment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of People Affecting the Coronavirus Disease Worldwide
- Spread of Coronavirus Disease Worldwide
- Government Initiatives and Support for Vaccine Development
- High Demand for Total Cure of Coronavirus Total Cure Treatment
- Unavailability of Government Approved Vaccines in the Market
- Huge Investment by Major Players for Coronavirus Vaccine Development
- Rising Demand from End-users
- High Future Demand for Vaccine from the Market
- Huge Investment for Research and Development of Coronavirus Vaccine
Recently Serum Institute of India, the world's largest vaccine maker announced that it is producing 40 million units of a coronavirus vaccine on trial in Oxford, without yet knowing if it works.
Key Target AudienceCoronavirus Vaccine Manufacturers, Distributors, Research Professionals, Emerging Companies and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase